[go: up one dir, main page]

US20130023658A1 - Tunably crosslinked polysaccharide compositions - Google Patents

Tunably crosslinked polysaccharide compositions Download PDF

Info

Publication number
US20130023658A1
US20130023658A1 US13/624,700 US201213624700A US2013023658A1 US 20130023658 A1 US20130023658 A1 US 20130023658A1 US 201213624700 A US201213624700 A US 201213624700A US 2013023658 A1 US2013023658 A1 US 2013023658A1
Authority
US
United States
Prior art keywords
hyaluronic acid
polyethylene glycol
present
crosslinking agent
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/624,700
Inventor
Dimitrios Stroumpoulis
Ahmet Tezel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to US13/624,700 priority Critical patent/US20130023658A1/en
Publication of US20130023658A1 publication Critical patent/US20130023658A1/en
Assigned to ALLERGAN, INC. reassignment ALLERGAN, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: STROUMPOULIS, DIMITRIOS, TEZEL, AHMET
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction

Definitions

  • the present invention relates to novel biocompatible polysaccharide gel compositions, methods of their manufacture and use, and the novel crosslinkers used to make them. More specifically, the present invention relates to novel compositions of hyaluronic acid gels that are crosslinked with a novel multifunctional crosslinker, and to methods of making such crosslinked hyaluronic acid gels.
  • Hyaluronic acid is a non-sulfated glycosaminoglycan that is distributed widely throughout the human body in connective, epithelial, and neural tissues. Hyaluronic acid is also a major component of skin, where it is involved in tissue repair. As skin ages and is repeatedly exposed to the sun's ultra violet rays, dermal cells decrease their production of hyaluronic acid and increase the rate of its degradation. Likewise, aging skin loses collagen, another natural substance necessary to keep skin youthful and resilient. Over time, the loss of hyaluronic acid and collagen causes aging skin to develop lines, wrinkles, and folds.
  • compositions of hyaluronic acid have been used in cosmetic applications to fill wrinkles, lines, folds, scars, and to enhance dermal tissue, for example, to plump lips. Because hyaluronic acid is natural to the human body, it is a generally well tolerated and fairly low risk skin augmentation product.
  • hyaluronic acid compositions contained particles, or microspheres, of hyaluronic acid suspended in a gel. These compositions, which are still in commercial use, tend to degrade within a few months after injection and thus require fairly frequent reinjection to maintain their skin augmenting effect. Specifically, hyaluronic acid is highly soluble in its natural state and has a rapid turnover through enzymatic and free radical metabolization.
  • compositions of cross-linked hyaluronic acid have been used for dermal augmentation.
  • These hyaluronic acid compositions are typically crosslinked with a bifunctional crosslinking agent, such as butanediol diglycidyl ether (BDDE), typically with a double ether bond connecting the HA molecules to form a less water soluble polymer hydrogel network that is more resistant to degradation, and thus requires less frequent reinjection, than the non-crosslinked hyaluronic acid compositions.
  • BDDE butanediol diglycidyl ether
  • Some such cross-linked compositions contain fairly large particles, around approximately 50-1000 ⁇ m each, of hyaluronic acid suspended in a gel. Others are a fairly uniform consistency gel matrix of hyaluronic acid.
  • the present invention relates to compositions of crosslinked hyaluronic acid, methods of their manufacture, and methods of their use. More specifically, the present invention relates to a process for the preparation of crosslinked hyaluronic acid, the process comprising contacting hyaluronic acid with a polyethylene glycol (PEG) based crosslinking agent.
  • PEG polyethylene glycol
  • the polyethylene glycol based crosslinker agent (or crosslinker) may be bifunctional, meaning it has a PEG backbone with two reactive groups for linking to the hyaluronic acid chains.
  • the polyethylene glycol based crosslinking agent (or crosslinker) may be “multifunctional,” having a PEG backbone with more than two reactive groups for linking to hyaluronic acid chains.
  • the process may additionally include contacting the hyaluronic acid with a non-polyethylene glycol based crosslinking agent, including but not limited to BDDE or divinyl sulfone (DVS).
  • a non-polyethylene glycol based crosslinking agent including but not limited to BDDE or divinyl sulfone (DVS).
  • the polyethylene based crosslinking agent may be tetrafunctional and the hyaluronic acid may be brought into contact with the tetrafunctional crosslinking agent and with a bifunctional crosslinking agent, such as, for example, BDDE.
  • the present invention also relates to a process for the preparation of crosslinked hyaluronic acid, the process comprising contacting hyaluronic acid with a multifunctional crosslinking agent.
  • the multifunctional crosslinking agent may be tri, tetra, penta, hexa, etc. functional (having more than two functional groups for reaction).
  • the process comprises contacting hyaluronic acid with a tetrafunctional crosslinking agent, such as a 4-Arm Star PEG epoxide which is further described herein.
  • the process may further comprise contacting the hyaluronic acid with a bifunctional crosslinking agent as well.
  • the hyaluronic acid may be contacted with a variety of bifunctional and multifunctional crosslinking agents, and such contact may occur sequentially in any order, or the hyaluronic acid may be reacted with the various crosslinking agents in one step.
  • the processes of the present invention may also comprise coating hyaluronic acid compositions with polyethylene glycol based pendants.
  • the polyethylene glycol based coating may be applied to crosslinked or uncrosslinked hyaluronic acid.
  • the crosslinked hyaluronic acid compositions made according to the present invention are further coated with polyethylene glycol based pendants.
  • the present invention also includes compositions for soft tissue augmentation, and in particular for dermal fillers, which are prepared according to the processes of the present invention. More specifically, the present invention includes a composition for soft tissue augmentation, and particularly for use as a dermal filler, the composition comprising hyaluronic acid that has been crosslinked with at least one type of polyethylene glycol crosslinking agent.
  • the polyethylene glycol based crosslinking agent(s) may be bifunctional, multifunctional, or a combination thereof.
  • a hyaluronic acid composition of the present invention has been crosslinked with a 4-Arm Star PEG epoxide.
  • compositions of the present invention may also comprise crosslinked hyaluronic acid compositions that have been prepared using more than one type of PEG crosslinking agent.
  • the compositions of the present invention may be prepared using a combination of polyethylene glycol based crosslinkers with varying numbers of functional groups and/or with varying lengths of ethylene glycol in their polymer chains or arms.
  • the compositions of the present invention may further comprise a polyethylene glycol based coating.
  • the present invention further relates to dermal filler compositions comprising hyaluronic acid that has been crosslinked using at least one multifunctional crosslinking agent.
  • the multifunctional crosslinking agent may be a multifunctional polyethylene glycol based crosslinking agent, such as a tetrafunctional polyethylene glycol based crosslinking agent, including, but not limited to, a 4-Arm Star PEG epoxide.
  • the dermal fillers of the present invention may also comprise hyaluronic acid that has been crosslinked with a multifunctional crosslinking agent, such as a tetrafunctional polyethylene glycol, and also with a bifunctional crosslinking agent, such as BDDE, DVS, or a bifunctional polyethylene glycol.
  • the present invention relates to methods for repair or augmentation of the soft tissue of a patient comprising the steps of selecting the soft tissue to be repaired or augmented and injecting a composition comprising a crosslinked hylauronic acid of the present invention, as described herein, into the selected soft tissue.
  • FIG. 1 depicts crosslinking of two hyaluronic acid chains with a bifunctional crosslinking agent.
  • FIG. 2 depicts crosslinking of four hyaluronic acid chains with a multifunctional crosslinking agent.
  • FIG. 3 depicts two chemical formulas for the tetrafunctional polyethylene glycol based crosslinking agent and its precursor of the present invention.
  • FIG. 4 is a graph showing the difference in mechanical strength between a sample a hyaluronic acid composition that was crosslinked with BDDE, and a hyaluronic acid composition that was crosslinked with a combination of BDDE and a 4-Arm Star PEG epoxide crosslinking agent of the present invention.
  • the present invention generally relates to hyaluronic acid compositions that are crosslinked using a multifunctional crosslinking agent, methods of using such compositions, and to the novel crosslinking agents used to make such hyaluronic acid compositions.
  • Such crosslinked hyaluronic acid compositions are useful for soft tissue augmentation, and particularly as dermal filler agents.
  • the crosslinkers of the present invention are polyethylene glycol (PEG) based crosslinkers.
  • PEG is a biocompatible polymer which is hydrophilic and inert. Because it is a polymer itself, its size (length) can be altered. Thus, the size of the PEG based crosslinker can be tuned based on the desired properties of the crosslinked hyaluronic acid.
  • the PEG based crosslinker 200 is bifunctional—both ends of the polymer chain are reactive (typically having epoxide ends) and thus capable of binding to strands of hyaluronic acid 100 .
  • the PEG based crosslinker comprises PEG of a plurality of chain lengths. The PEG based crosslinker can be made according to any PEG synthesis methods known to one of ordinary skill in the art.
  • the PEG based crosslinkers of the present invention may be used on their own or in combination with any another crosslinking agent suitable for making crosslinked hyaluronic acid.
  • a combination of PEG based crosslinkers of the present invention and BDDE is used to make a crosslinked hyaluronic acid composition.
  • the crosslinker of the present invention is a multifunctional crosslinker.
  • multifunctional means having more than two reactive sites on the crosslinking agent.
  • the multifunctional crosslinker 300 is able to bind more chains of hyaluronic acid 100 to one another than a bifunctional crosslinker.
  • the multifunctional crosslinker results in hyaluronic acid compositions with greater mechanical strength (G′).
  • the multifunctional crosslinkers of the present invention also improve the degradation of the resulting hyaluronic acid composition.
  • the multifunctional crosslinkers of the present invention increase the probability of each crosslinking molecule reacting with at least one hyaluronic acid strand, thereby facilitating purification and removal of unreacted crosslinking agents from the final hyaluronic acid composition.
  • the multifunctional crosslinker is trifunctional (contains 3 active sites). In another embodiment, the multifunctional crosslinker is tetrafunctional. In yet another embodiment, the multifunctional crosslinker is pentafunctional. In still another embodiment, the multifunctional crosslinker is hexafunctional or more. Indeed, the number of functional sites on the crosslinker of the present invention is limited only by the ability of the hyaluronic acid chains to bind to the resulting active sites on the crosslinker due to, e.g., geometry and steric hindrance. In another embodiment of the present invention, a crosslinker composition comprises multifunctional crosslinkers of at least two different functionalities (e.g.
  • a multifunctional crosslinker is combined with a bifunctional crosslinker in varying ratios to create hyaluronic acid compositions with varying mechanical strength.
  • Table 1 shows a few sample bifunctional to multifunctional crosslinker ratios and the mechanical strengths of the resulting hyaluronic acid gels.
  • the multifunctional crosslinker of the present invention may be a multifunctional PEG based crosslinker.
  • a tetrafunctional PEG based crosslinker of the present invention is shown in FIG. 3 .
  • the present invention relates to a tetrafunctional PEG crosslinker precursor.
  • the tetrafunctional PEG crosslinker precursor may further be reacted with an epoxide to create a novel 4-Arm Star PEG epoxide crosslinker.
  • the epoxide tetrafunctional PEG crosslinker shown in FIG. 3 may be made from a base poly-alcohol molecule (i.e.
  • Epoxide groups can be attached to the base poly-alcohol molecule by deprotonating the hydroxyl groups and reacting with epichlorohydrin. The epoxide rings can subsequently react with the hydroxyl groups of the PEG chains under basic conditions. In the final step of the cross-linker preparation, epoxide groups can be attached to each end of the PEG chains, thus enabling the reaction of the crosslinker with the polysaccharide molecule.
  • tetrafunctional PEG based crosslinkers are of tunable size.
  • the crosslinkers may have a variety of polymer lengths in their arms, thereby affecting their mechanical properties.
  • a bifunctional crosslinker such as, for example, the bifunctional PEG crosslinkers of the present invention, BDDE, DVS, and/or 1,2,7,8-diepoxyoctane, in varying ratios, the mechanical strength and hardness of the final hyaluronic acid composition may be tuned as desired.
  • the present invention also relates to crosslinked hyaluronic acid compositions that are made using the crosslinking agents of the present invention.
  • the hyaluronic acid compositions of the present invention comprise a PEG based crosslinker.
  • the hyaluronic acid compositions of the present invention comprise a multifunctional PEG based crosslinker.
  • the hyaluronic acid compositions comprise a tetrafunctional PEG based crosslinker.
  • the hyaluronic acid compositions comprise a 4-Arm Star PEG epoxide cross linker.
  • the hyaluronic acid compositions comprise multifunctional crosslinkers as well as bifunctional crosslinkers.
  • the hyaluronic acid compositions of the present invention may be fairly uniform gels or they may be ground into particles which can be further suspended in a gel.
  • the hyaluronic acid composition comprises hyaluronic acid that is made with a multifunctional crosslinking agent and then ground into particles, and a gel of hyaluronic acid made with a multifunctional and/or bifunctional crosslinking agent in which the particles are suspended.
  • hyaluronic acid compositions are further coated in PEG based pendant.
  • PEG offers good degradation resistance to hyaluronic acid.
  • Crosslinked or noncrosslinked hyaluronic acid particles can be coated with PEG based pendants to enhance their in vivo longevity.
  • the crosslinked hyaluronic acid compositions of the present invention are ground into particles and the particles are coated with PEG based pendants. The particles may typically be about 100 ⁇ m to 1000 ⁇ m and the coating may typically range from 2 nm to 50 nm in thickness.
  • the present invention also relates to methods of making hyaluronic acid compositions that are crosslinked with a PEG based crosslinker.
  • hyaluronic acid is brought into contact with a bifunctional PEG based crosslinker and allowed to react.
  • hyaluronic acid is brought into contact with a quantity of a bifunctional crosslinker, and is then brought into contact with a quantity of a multifunctional crosslinker.
  • the hyaluronic acid may be reacted with more than one crosslinker in either a step-wise fashion, with a lower functionality crosslinker being brought into contact first or with a higher functionality crosslinker being brought into contact first.
  • the hyaluronic acid may be reacted with a plurality of crosslinkers in one step.
  • Another aspect of the present invention is methods of using the novel hyaluronic acid compositions of the present invention to augment soft tissue.
  • the novel hyaluronic acid compositions of the present invention are used as dermal fillers to fill undesired lines, wrinkles, and/or folds in a patient's skin.
  • a multifunctional crosslinker of the present invention may be prepared from a base polyalcohol.
  • pentaerythritol i.e. for the tetrafunctional PEG crosslinker
  • 100 mg of sodium hydride and subsequently with 370 mg of epichlorohydrin to attach the epoxide groups.
  • the precursor can be reacted with an equimolar amount of epichlorohydrin as described above to produce the tetrafunctional crosslinker.
  • One embodiment of a hyaluronic acid gel according to the present invention may be prepared as follows.
  • NaHA sodium hyaluronate fibers
  • BDDE 1,4 butanediol diglycidyl ether
  • Example 2 To compare the characteristics of a crosslinked hyaluronic acid of the present invention to a prior art type of crosslinked hyaluronic acid, the method disclosed in Example 2 was used to prepare a batch of the novel tunably crosslinked hyaluronic acid. A similar method was used to prepare a batch of a known crosslinked hyaluronic acid, using BDDE as the only crosslinking agent (not adding any of the novel 4-Arm Star PEG epoxide) such that the molar ratio of HA to crosslinker was the same as in Example 2.
  • Samples from the two batches were then compared using strain sweep tests to determine gel hardness as an indicator of the degree of crosslinking of each sample.
  • the strain sweep tests were performed on an ARES rheometer using a 50 mm parallel plate set-up. Approximately 2 to 3 ml of each sample was placed at the center of the lower plate and the gap was set to 1 mm. The test was performed at 5 Hz frequency for a range of 1-250% strain. At low values of strain, the plateau in the elastic or storage modulus G′ quantifies the gel hardness.
  • FIG. 4 demonstrates graphically the results of measurements made on the filling gels prepared according to the invention in comparison to prior art hydrogels. As shown in FIG. 4 , the G′ plateau for the hydrogel of the present invention is significantly higher than that of the prior art gel. The hydrogel of the present invention is harder and is more highly cross-linked than the prior art gel.
  • PEG based pendant coated hydrogel particles may be prepared by mixing 380 mg of hydrogel particles, such as Captique®, with 0-100 mg of epoxide terminated monofunctional PEG 2000 Da and 0.5 ml of sodium hydroxide (0.01-1% wt) and left to react for 1-10 hrs at 40-70° C.
  • the resulting PEG based pendant coated particles may be neutralized with an equimolar amount of hydrochloric acid.
  • Coated particles may be compared to non-coated particles using an enzymatic degradation assay.
  • a 0.1-10 mg quantity of hyaluronidase may be added to the hyaluronic acid particles for 10-250 mins at 37° C. followed by 0.1 ml of a 0.8 M potassium tetraborate solution and heating at 100° C. for 10 mins.
  • the samples may be supplemented with 3 ml of a 10% wt p-dimethylaminobenzaldehyde solution in acetic acid and incubated at 37° C. for 10-120 mins.
  • the absorbance at 585 nm may be used to quantify the hyaluronic acid degradation in each sample.
  • the optical density (OD) values are reported in Table 2. As more PEG based pendant is used to coat the hyaluronic acid particles, the system becomes less susceptible to enzymatic degradation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Transplantation (AREA)
  • Polymers & Plastics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials For Medical Uses (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Resins (AREA)

Abstract

The present invention generally relates to novel biocompatible crosslinked polysaccharide gel compositions, methods of their manufacture and use, and the novel crosslinkers used to make them. In one aspect of the invention, a novel polyethylene glycol crosslinking agent is described for crosslinking hyaluronic acid. In another aspect of the invention, novel crosslinking agents comprising more than two functional groups are described. These multifunctional crosslinking agents can be used on their own to crosslink hyaluronic acid, or they may be combined with bifunctional crosslinking agents in varying ratios to make hyaluronic acid of tunable mechanical strength and hardness. The present invention also discloses novel hyaluronic acid compositions that have been coated with polyethylene glycol and methods of their use.

Description

    RELATED APPLICATION
  • This application is a divisional of U.S. Patent Application No. 12/178,574, filed Jul. 23, 2008, which claims priority to U.S. Provisional Patent Application No. 60/952,770, filed on Jul. 30, 2007, each of which are incorporated herein by reference.
    • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • The present invention relates to novel biocompatible polysaccharide gel compositions, methods of their manufacture and use, and the novel crosslinkers used to make them. More specifically, the present invention relates to novel compositions of hyaluronic acid gels that are crosslinked with a novel multifunctional crosslinker, and to methods of making such crosslinked hyaluronic acid gels.
  • 2. Background Art
  • Hyaluronic acid is a non-sulfated glycosaminoglycan that is distributed widely throughout the human body in connective, epithelial, and neural tissues. Hyaluronic acid is also a major component of skin, where it is involved in tissue repair. As skin ages and is repeatedly exposed to the sun's ultra violet rays, dermal cells decrease their production of hyaluronic acid and increase the rate of its degradation. Likewise, aging skin loses collagen, another natural substance necessary to keep skin youthful and resilient. Over time, the loss of hyaluronic acid and collagen causes aging skin to develop lines, wrinkles, and folds.
  • In the past several years, compositions of hyaluronic acid have been used in cosmetic applications to fill wrinkles, lines, folds, scars, and to enhance dermal tissue, for example, to plump lips. Because hyaluronic acid is natural to the human body, it is a generally well tolerated and fairly low risk skin augmentation product.
  • Originally, hyaluronic acid compositions contained particles, or microspheres, of hyaluronic acid suspended in a gel. These compositions, which are still in commercial use, tend to degrade within a few months after injection and thus require fairly frequent reinjection to maintain their skin augmenting effect. Specifically, hyaluronic acid is highly soluble in its natural state and has a rapid turnover through enzymatic and free radical metabolization.
  • More recently, compositions of cross-linked hyaluronic acid have been used for dermal augmentation. These hyaluronic acid compositions are typically crosslinked with a bifunctional crosslinking agent, such as butanediol diglycidyl ether (BDDE), typically with a double ether bond connecting the HA molecules to form a less water soluble polymer hydrogel network that is more resistant to degradation, and thus requires less frequent reinjection, than the non-crosslinked hyaluronic acid compositions. Some such cross-linked compositions contain fairly large particles, around approximately 50-1000 μm each, of hyaluronic acid suspended in a gel. Others are a fairly uniform consistency gel matrix of hyaluronic acid.
  • While these known crosslinked hyaluronic acid compositions last longer than their noncrosslinked counterparts, their duration is typically twelve months or less, thus still requiring fairly frequent reinjection. It is thus desirable to develop a hyaluronic acid composition that is biocompatible and useful as a dermal filler, but has a longer useful lifetime upon injection. Specifically, it is desirable to develop a hyaluronic acid composition that is biocompatible and injectable, but that has a higher mechanical strength, a greater resistance to enzymatic degradation, and a higher water retention than currently available compositions.
    • BRIEF SUMMARY OF THE INVENTION
  • The present invention relates to compositions of crosslinked hyaluronic acid, methods of their manufacture, and methods of their use. More specifically, the present invention relates to a process for the preparation of crosslinked hyaluronic acid, the process comprising contacting hyaluronic acid with a polyethylene glycol (PEG) based crosslinking agent. The polyethylene glycol based crosslinker agent (or crosslinker) may be bifunctional, meaning it has a PEG backbone with two reactive groups for linking to the hyaluronic acid chains. Or, the polyethylene glycol based crosslinking agent (or crosslinker) may be “multifunctional,” having a PEG backbone with more than two reactive groups for linking to hyaluronic acid chains. The process may additionally include contacting the hyaluronic acid with a non-polyethylene glycol based crosslinking agent, including but not limited to BDDE or divinyl sulfone (DVS). According to some of the processes of the present invention for making a crosslinked hyaluronic acid, the polyethylene based crosslinking agent may be tetrafunctional and the hyaluronic acid may be brought into contact with the tetrafunctional crosslinking agent and with a bifunctional crosslinking agent, such as, for example, BDDE.
  • The present invention also relates to a process for the preparation of crosslinked hyaluronic acid, the process comprising contacting hyaluronic acid with a multifunctional crosslinking agent. The multifunctional crosslinking agent may be tri, tetra, penta, hexa, etc. functional (having more than two functional groups for reaction). In one embodiment of the present invention, the process comprises contacting hyaluronic acid with a tetrafunctional crosslinking agent, such as a 4-Arm Star PEG epoxide which is further described herein. The process may further comprise contacting the hyaluronic acid with a bifunctional crosslinking agent as well. The hyaluronic acid may be contacted with a variety of bifunctional and multifunctional crosslinking agents, and such contact may occur sequentially in any order, or the hyaluronic acid may be reacted with the various crosslinking agents in one step.
  • The processes of the present invention may also comprise coating hyaluronic acid compositions with polyethylene glycol based pendants. The polyethylene glycol based coating may be applied to crosslinked or uncrosslinked hyaluronic acid. In one preferred embodiment, the crosslinked hyaluronic acid compositions made according to the present invention are further coated with polyethylene glycol based pendants.
  • The present invention also includes compositions for soft tissue augmentation, and in particular for dermal fillers, which are prepared according to the processes of the present invention. More specifically, the present invention includes a composition for soft tissue augmentation, and particularly for use as a dermal filler, the composition comprising hyaluronic acid that has been crosslinked with at least one type of polyethylene glycol crosslinking agent. The polyethylene glycol based crosslinking agent(s) may be bifunctional, multifunctional, or a combination thereof. In one embodiment, a hyaluronic acid composition of the present invention has been crosslinked with a 4-Arm Star PEG epoxide. The compositions of the present invention may also comprise crosslinked hyaluronic acid compositions that have been prepared using more than one type of PEG crosslinking agent. For example, the compositions of the present invention may be prepared using a combination of polyethylene glycol based crosslinkers with varying numbers of functional groups and/or with varying lengths of ethylene glycol in their polymer chains or arms. The compositions of the present invention may further comprise a polyethylene glycol based coating.
  • The present invention further relates to dermal filler compositions comprising hyaluronic acid that has been crosslinked using at least one multifunctional crosslinking agent. The multifunctional crosslinking agent may be a multifunctional polyethylene glycol based crosslinking agent, such as a tetrafunctional polyethylene glycol based crosslinking agent, including, but not limited to, a 4-Arm Star PEG epoxide. The dermal fillers of the present invention may also comprise hyaluronic acid that has been crosslinked with a multifunctional crosslinking agent, such as a tetrafunctional polyethylene glycol, and also with a bifunctional crosslinking agent, such as BDDE, DVS, or a bifunctional polyethylene glycol.
  • In yet another aspect, the present invention relates to methods for repair or augmentation of the soft tissue of a patient comprising the steps of selecting the soft tissue to be repaired or augmented and injecting a composition comprising a crosslinked hylauronic acid of the present invention, as described herein, into the selected soft tissue.
  • The foregoing and other aspects, features, details, utilities, and advantages of the present invention will be apparent from reading the following description and claims, and from reviewing the accompanying drawings.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 depicts crosslinking of two hyaluronic acid chains with a bifunctional crosslinking agent.
  • FIG. 2 depicts crosslinking of four hyaluronic acid chains with a multifunctional crosslinking agent.
  • FIG. 3 depicts two chemical formulas for the tetrafunctional polyethylene glycol based crosslinking agent and its precursor of the present invention.
  • FIG. 4 is a graph showing the difference in mechanical strength between a sample a hyaluronic acid composition that was crosslinked with BDDE, and a hyaluronic acid composition that was crosslinked with a combination of BDDE and a 4-Arm Star PEG epoxide crosslinking agent of the present invention.
    •  DETAILED DESCRIPTION OF THE INVENTION
  • The present invention generally relates to hyaluronic acid compositions that are crosslinked using a multifunctional crosslinking agent, methods of using such compositions, and to the novel crosslinking agents used to make such hyaluronic acid compositions. Such crosslinked hyaluronic acid compositions are useful for soft tissue augmentation, and particularly as dermal filler agents.
  • One aspect of this invention relates to novel catalysts for the crosslinking of hyaluronic acid. In one embodiment, the crosslinkers of the present invention are polyethylene glycol (PEG) based crosslinkers. PEG is a biocompatible polymer which is hydrophilic and inert. Because it is a polymer itself, its size (length) can be altered. Thus, the size of the PEG based crosslinker can be tuned based on the desired properties of the crosslinked hyaluronic acid. As shown in FIG. 1, in one embodiment of the present invention, the PEG based crosslinker 200 is bifunctional—both ends of the polymer chain are reactive (typically having epoxide ends) and thus capable of binding to strands of hyaluronic acid 100. In another embodiment of the present invention, the PEG based crosslinker comprises PEG of a plurality of chain lengths. The PEG based crosslinker can be made according to any PEG synthesis methods known to one of ordinary skill in the art.
  • The PEG based crosslinkers of the present invention may be used on their own or in combination with any another crosslinking agent suitable for making crosslinked hyaluronic acid. In one embodiment of the present invention, a combination of PEG based crosslinkers of the present invention and BDDE is used to make a crosslinked hyaluronic acid composition.
  • In another embodiment, the crosslinker of the present invention is a multifunctional crosslinker. As used herein, multifunctional means having more than two reactive sites on the crosslinking agent. As shown in FIG. 2, the multifunctional crosslinker 300 is able to bind more chains of hyaluronic acid 100 to one another than a bifunctional crosslinker. Thus, the multifunctional crosslinker results in hyaluronic acid compositions with greater mechanical strength (G′). The multifunctional crosslinkers of the present invention also improve the degradation of the resulting hyaluronic acid composition. Moreover, the multifunctional crosslinkers of the present invention increase the probability of each crosslinking molecule reacting with at least one hyaluronic acid strand, thereby facilitating purification and removal of unreacted crosslinking agents from the final hyaluronic acid composition.
  • In one embodiment of the present invention, the multifunctional crosslinker is trifunctional (contains 3 active sites). In another embodiment, the multifunctional crosslinker is tetrafunctional. In yet another embodiment, the multifunctional crosslinker is pentafunctional. In still another embodiment, the multifunctional crosslinker is hexafunctional or more. Indeed, the number of functional sites on the crosslinker of the present invention is limited only by the ability of the hyaluronic acid chains to bind to the resulting active sites on the crosslinker due to, e.g., geometry and steric hindrance. In another embodiment of the present invention, a crosslinker composition comprises multifunctional crosslinkers of at least two different functionalities (e.g. a combination of tetrafunctional crosslinkers with hexafunctional crosslinkers). In still a further embodiment, a multifunctional crosslinker is combined with a bifunctional crosslinker in varying ratios to create hyaluronic acid compositions with varying mechanical strength. Table 1 shows a few sample bifunctional to multifunctional crosslinker ratios and the mechanical strengths of the resulting hyaluronic acid gels.
  • In a further aspect, the multifunctional crosslinker of the present invention may be a multifunctional PEG based crosslinker. A tetrafunctional PEG based crosslinker of the present invention is shown in FIG. 3. As shown in FIG. 3, in one embodiment, the present invention relates to a tetrafunctional PEG crosslinker precursor. As further shown in FIG. 3, the tetrafunctional PEG crosslinker precursor may further be reacted with an epoxide to create a novel 4-Arm Star PEG epoxide crosslinker. The epoxide tetrafunctional PEG crosslinker shown in FIG. 3 may be made from a base poly-alcohol molecule (i.e. pentaerythritol) by attaching epoxide groups and reacting with hydroxyl-PEG chains of the desired length and branching. Epoxide groups can be attached to the base poly-alcohol molecule by deprotonating the hydroxyl groups and reacting with epichlorohydrin. The epoxide rings can subsequently react with the hydroxyl groups of the PEG chains under basic conditions. In the final step of the cross-linker preparation, epoxide groups can be attached to each end of the PEG chains, thus enabling the reaction of the crosslinker with the polysaccharide molecule.
  • As with the bifunctional PEG based crosslinkers, described above, tetrafunctional PEG based crosslinkers (including the 4-Arm Star PEG epoxide) are of tunable size. As shown in FIG. 3, the crosslinkers may have a variety of polymer lengths in their arms, thereby affecting their mechanical properties. Moreover, by mixing the tetrafunctional based PEG crosslinkers of the present invention with a bifunctional crosslinker, such as, for example, the bifunctional PEG crosslinkers of the present invention, BDDE, DVS, and/or 1,2,7,8-diepoxyoctane, in varying ratios, the mechanical strength and hardness of the final hyaluronic acid composition may be tuned as desired.
  • The present invention also relates to crosslinked hyaluronic acid compositions that are made using the crosslinking agents of the present invention. In one embodiment, the hyaluronic acid compositions of the present invention comprise a PEG based crosslinker. In a further embodiment, the hyaluronic acid compositions of the present invention comprise a multifunctional PEG based crosslinker. In yet a further embodiment, the hyaluronic acid compositions comprise a tetrafunctional PEG based crosslinker. And in still a further embodiment, the hyaluronic acid compositions comprise a 4-Arm Star PEG epoxide cross linker. In other embodiments, the hyaluronic acid compositions comprise multifunctional crosslinkers as well as bifunctional crosslinkers. The hyaluronic acid compositions of the present invention may be fairly uniform gels or they may be ground into particles which can be further suspended in a gel. In one embodiment of the present invention, the hyaluronic acid composition comprises hyaluronic acid that is made with a multifunctional crosslinking agent and then ground into particles, and a gel of hyaluronic acid made with a multifunctional and/or bifunctional crosslinking agent in which the particles are suspended.
  • In yet another aspect of the present invention, hyaluronic acid compositions are further coated in PEG based pendant. As a biocompatible, inert, and hydrophilic polymer, PEG offers good degradation resistance to hyaluronic acid. Crosslinked or noncrosslinked hyaluronic acid particles can be coated with PEG based pendants to enhance their in vivo longevity. In one embodiment, the crosslinked hyaluronic acid compositions of the present invention are ground into particles and the particles are coated with PEG based pendants. The particles may typically be about 100 μm to 1000 μm and the coating may typically range from 2 nm to 50 nm in thickness.
  • The present invention also relates to methods of making hyaluronic acid compositions that are crosslinked with a PEG based crosslinker. In one embodiment, hyaluronic acid is brought into contact with a bifunctional PEG based crosslinker and allowed to react. In a further embodiment, hyaluronic acid is brought into contact with a quantity of a bifunctional crosslinker, and is then brought into contact with a quantity of a multifunctional crosslinker. The hyaluronic acid may be reacted with more than one crosslinker in either a step-wise fashion, with a lower functionality crosslinker being brought into contact first or with a higher functionality crosslinker being brought into contact first. Or, the hyaluronic acid may be reacted with a plurality of crosslinkers in one step.
  • Another aspect of the present invention is methods of using the novel hyaluronic acid compositions of the present invention to augment soft tissue. In one embodiment, the novel hyaluronic acid compositions of the present invention are used as dermal fillers to fill undesired lines, wrinkles, and/or folds in a patient's skin.
  • The following examples provide further detail regarding some of the embodiments of the present invention.
    • EXAMPLE 1
  • A multifunctional crosslinker of the present invention may be prepared from a base polyalcohol. For example, 136 mg of pentaerythritol (i.e. for the tetrafunctional PEG crosslinker) may be reacted with 100 mg of sodium hydride and subsequently with 370 mg of epichlorohydrin to attach the epoxide groups. 5000 mg of hydroxyl PEG chains (i.e. MW=1.25 k) may be reacted with the epoxide terminated poly-alcohol under basic conditions (i.e. in a NaOH solution) to yield a tetrafunctional PEG hydroxyl terminated crosslinker precursor. The precursor can be reacted with an equimolar amount of epichlorohydrin as described above to produce the tetrafunctional crosslinker.
    • EXAMPLE 2
  • One embodiment of a hyaluronic acid gel according to the present invention may be prepared as follows.
  • One gram of sodium hyaluronate fibers (NaHA, Mw=0.5-3 MDa) is mixed with 5-10 grams of 0.01-1% sodium hudroxide solution and the mixture is left to hydrate for 1 to 5 hours. Then 20-200 mg of 1,4 butanediol diglycidyl ether (BDDE) and 0.05-2 g of 4-Arm star PEG epoxide (Mw=200-10,000 Da) are added to the NaHA gel. The mixture is mechanically homogenized, then placed in a 40-70° C. oven for 1 to 10 hours. The resulting crosslinked hydrogel is neutralized with an equimolar amount of hydrochloric acid and swelled in a phosphate buffer (PBS, pH=7.4). This hydrogel may then be mechanically homogenized.
    • EXAMPLE 3
  • To compare the characteristics of a crosslinked hyaluronic acid of the present invention to a prior art type of crosslinked hyaluronic acid, the method disclosed in Example 2 was used to prepare a batch of the novel tunably crosslinked hyaluronic acid. A similar method was used to prepare a batch of a known crosslinked hyaluronic acid, using BDDE as the only crosslinking agent (not adding any of the novel 4-Arm Star PEG epoxide) such that the molar ratio of HA to crosslinker was the same as in Example 2.
  • Samples from the two batches were then compared using strain sweep tests to determine gel hardness as an indicator of the degree of crosslinking of each sample. The strain sweep tests were performed on an ARES rheometer using a 50 mm parallel plate set-up. Approximately 2 to 3 ml of each sample was placed at the center of the lower plate and the gap was set to 1 mm. The test was performed at 5 Hz frequency for a range of 1-250% strain. At low values of strain, the plateau in the elastic or storage modulus G′ quantifies the gel hardness.
  • FIG. 4 demonstrates graphically the results of measurements made on the filling gels prepared according to the invention in comparison to prior art hydrogels. As shown in FIG. 4, the G′ plateau for the hydrogel of the present invention is significantly higher than that of the prior art gel. The hydrogel of the present invention is harder and is more highly cross-linked than the prior art gel.
    • EXAMPLE 4
  • Six samples of crosslinked hyaluronic acid were prepared using bifunctional PEG and 4-Arm Star PEG epoxide crosslinkers. In each sample, the ratio of bifunctional PEG to 4-Arm Star PEG epoxide was varied, such that the molar ratio of HA to total crosslinker remained the same for all six samples. The mechanical strength of each sample was tested using the same method described above. The plateau in G′ at low strain values is reported in the Table 1 below. As shown in Table 1, the plateau G′ value at low strain increases as bifunctional crosslinker is replaced by equimolar amounts of the tetrafunctional crosslinker, indicating an increased degree of crosslinking.
  • TABLE 1
    % Bifunctional PEG % 4-Arm Star PEG Epoxide G′ (Pa)
    100 0 180
    90 10 190
    85 15 205
    75 25 252
    50 50 360
    25 75 400
    • EXAMPLE 5
  • PEG based pendant coated hydrogel particles may be prepared by mixing 380 mg of hydrogel particles, such as Captique®, with 0-100 mg of epoxide terminated monofunctional PEG 2000 Da and 0.5 ml of sodium hydroxide (0.01-1% wt) and left to react for 1-10 hrs at 40-70° C. The resulting PEG based pendant coated particles may be neutralized with an equimolar amount of hydrochloric acid.
  • Coated particles may be compared to non-coated particles using an enzymatic degradation assay. A 0.1-10 mg quantity of hyaluronidase may be added to the hyaluronic acid particles for 10-250 mins at 37° C. followed by 0.1 ml of a 0.8 M potassium tetraborate solution and heating at 100° C. for 10 mins. The samples may be supplemented with 3 ml of a 10% wt p-dimethylaminobenzaldehyde solution in acetic acid and incubated at 37° C. for 10-120 mins. The absorbance at 585 nm may be used to quantify the hyaluronic acid degradation in each sample. The optical density (OD) values are reported in Table 2. As more PEG based pendant is used to coat the hyaluronic acid particles, the system becomes less susceptible to enzymatic degradation.
  • TABLE 2
    Sample (PEG:HA ratio) Optical Density (OD) at 585 nm
    A (0:1) 0.750
    B (2:1) 0.400
    C (10:1) 0.260
  • Although only a few embodiments of this invention have been described above with a certain degree of particularity, those skilled in the art could make numerous alterations to the disclosed embodiments without departing from the spirit or scope of this invention. It is intended that all matter contained in the above description or shown in the accompanying drawings shall be interpreted as illustrative only and not limiting. Changes in detail may be made without departing from the spirit of the invention as defined in the appended claims.

Claims (13)

1. A process for the preparation of crosslinked hyaluronic acid, said process comprising:
contacting hyaluronic acid with a polyethylene glycol based crosslinking agent; and
contacting the hyaluronic acid with a non-polyethylene glycol based crosslinking agent.
2. The process of claim 1, wherein the polyethylene glycol based crosslinking agent is bifunctional.
3. The process of claim 1, wherein the polyethylene glycol based crosslinking agent is multifunctional.
4. The process of claim 1, wherein the non-polyethylene glycol based crosslinking agent is BDDE.
5. The process of claim 1, wherein the polyethylene glycol based crosslinking agent is tetrafunctional and the non-polyethylene glycol based crosslinking agent is BDDE.
6. The process of claim 1, wherein the polyethylene glycol based crosslinking agent is 4-Arm Star PEG epoxide.
7. A composition for soft tissue augmentation obtained by a process according to claim 1.
8. A composition for soft tissue augmentation obtained by a process according to claim 5.
9. A composition for soft tissue augmentation, said composition comprising hyaluronic acid that has been crosslinked with at least two types of polyethylene glycol based crosslinking agents, wherein at least one of the at least two types of polyethylene glycol based crosslinking agents is bifunctional.
10. The composition of claim 9, wherein said at least one type of polyethylene glycol based crosslinking agent is multifunctional.
11. The composition of claim 9, wherein said at least one type of polyethylene glycol based crosslinking agent is a 4-Arm Star PEG epoxide.
12. The composition of claim 9 for use as a dermal filler.
13. The composition of claim 11 for use as a dermal filler.
US13/624,700 2007-07-30 2012-09-21 Tunably crosslinked polysaccharide compositions Abandoned US20130023658A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/624,700 US20130023658A1 (en) 2007-07-30 2012-09-21 Tunably crosslinked polysaccharide compositions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95277007P 2007-07-30 2007-07-30
US12/178,574 US8318695B2 (en) 2007-07-30 2008-07-23 Tunably crosslinked polysaccharide compositions
US13/624,700 US20130023658A1 (en) 2007-07-30 2012-09-21 Tunably crosslinked polysaccharide compositions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/178,574 Division US8318695B2 (en) 2007-07-30 2008-07-23 Tunably crosslinked polysaccharide compositions

Publications (1)

Publication Number Publication Date
US20130023658A1 true US20130023658A1 (en) 2013-01-24

Family

ID=39769477

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/178,574 Expired - Fee Related US8318695B2 (en) 2007-07-30 2008-07-23 Tunably crosslinked polysaccharide compositions
US13/624,700 Abandoned US20130023658A1 (en) 2007-07-30 2012-09-21 Tunably crosslinked polysaccharide compositions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/178,574 Expired - Fee Related US8318695B2 (en) 2007-07-30 2008-07-23 Tunably crosslinked polysaccharide compositions

Country Status (11)

Country Link
US (2) US8318695B2 (en)
EP (1) EP2178923A1 (en)
JP (2) JP5518709B2 (en)
KR (1) KR20100046038A (en)
CN (2) CN102850468A (en)
AU (1) AU2008282541B2 (en)
BR (1) BRPI0815045A2 (en)
CA (1) CA2695179A1 (en)
MX (1) MX2010001219A (en)
NZ (2) NZ583031A (en)
WO (1) WO2009018076A1 (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8853184B2 (en) 2007-11-30 2014-10-07 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US8921338B2 (en) 2010-03-12 2014-12-30 Allergan Industrie, Sas Fluid compositions for improving skin conditions
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US9089519B2 (en) 2008-08-04 2015-07-28 Allergan Industrie Sas Hyaluronic acid-based gels including lidocaine
US9228027B2 (en) 2008-09-02 2016-01-05 Allergan Holdings France S.A.S. Threads of Hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
US9265761B2 (en) 2007-11-16 2016-02-23 Allergan, Inc. Compositions and methods for treating purpura
US9333160B2 (en) 2010-01-13 2016-05-10 Allergan Industrie, Sas Heat stable hyaluronic acid compositions for dermatological use
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US9737633B2 (en) 2011-06-03 2017-08-22 Allergan, Inc. Dermal filler compositions including antioxidants
CN107936272A (en) * 2017-11-27 2018-04-20 华熙福瑞达生物医药有限公司 A kind of preparation method of 3D cross-linked-hyaluronic acid salt gels for radiotherapy protection and products thereof
CN107955194A (en) * 2017-11-29 2018-04-24 桂林华诺威生物科技有限公司 The preparation method of high quality cross-linking sodium hyaluronate gel
CN108774329A (en) * 2018-06-13 2018-11-09 浙江景嘉医疗科技有限公司 A kind of preparation method of medical cross-linking sodium hyaluronate gel
WO2019130358A1 (en) * 2017-12-29 2019-07-04 Matex Lab S.P.A. Method to prepare a filler with a hyaluronic acid base
WO2019130357A1 (en) * 2017-12-29 2019-07-04 Matex Lab S.P.A. Method to prepare a filler with a hyaluronic acid base using specific crosslinking agents
US10434214B2 (en) 2011-09-06 2019-10-08 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US10722444B2 (en) 2014-09-30 2020-07-28 Allergan Industrie, Sas Stable hydrogel compositions including additives
US10905797B2 (en) 2010-03-22 2021-02-02 Allergan, Inc. Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US11083684B2 (en) 2011-06-03 2021-08-10 Allergan Industrie, Sas Dermal filler compositions
US11844878B2 (en) 2011-09-06 2023-12-19 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
US12324868B2 (en) 2015-02-13 2025-06-10 Allergan Industrie, Sas Implants for sculpting, augmenting or correcting facial features such as the chin

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2861734B1 (en) 2003-04-10 2006-04-14 Corneal Ind CROSSLINKING OF LOW AND HIGH MOLECULAR MASS POLYSACCHARIDES; PREPARATION OF INJECTABLE SINGLE PHASE HYDROGELS; POLYSACCHARIDES AND HYDROGELS OBTAINED
US20060073208A1 (en) 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
AU2008256819A1 (en) * 2007-05-23 2008-12-04 Allergan, Inc. Cross-linked collagen and uses thereof
US8318695B2 (en) * 2007-07-30 2012-11-27 Allergan, Inc. Tunably crosslinked polysaccharide compositions
US20110077737A1 (en) * 2007-07-30 2011-03-31 Allergan, Inc. Tunably Crosslinked Polysaccharide Compositions
US20120071437A1 (en) * 2007-07-30 2012-03-22 Allergan, Inc. Tunable crosslinked polysaccharide compositions
US8697044B2 (en) * 2007-10-09 2014-04-15 Allergan, Inc. Crossed-linked hyaluronic acid and collagen and uses thereof
US8394784B2 (en) * 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
US20090143348A1 (en) * 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
US20100098772A1 (en) * 2008-10-21 2010-04-22 Allergan, Inc. Drug delivery systems and methods for treating neovascularization
JP4885245B2 (en) * 2009-01-15 2012-02-29 日本航空電子工業株式会社 RD converter and angle detection device
WO2011014432A1 (en) 2009-07-30 2011-02-03 Carbylan Biosurgery, Inc. Modified hyaluronic acid polymer compositions and related methods
MX2012004499A (en) 2009-10-29 2012-05-29 Ascendis Pharma As Sterilization of biodegradable hydrogels.
US20110171311A1 (en) * 2010-01-13 2011-07-14 Allergan Industrie, Sas Stable hydrogel compositions including additives
US20110171310A1 (en) * 2010-01-13 2011-07-14 Allergan Industrie, Sas Hydrogel compositions comprising vasoconstricting and anti-hemorrhagic agents for dermatological use
US20110171286A1 (en) * 2010-01-13 2011-07-14 Allergan, Inc. Hyaluronic acid compositions for dermatological use
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
CN102226009B (en) * 2011-06-09 2013-04-10 西安力邦制药有限公司 Method for preparing crosslinking hyaluronic acid gel
TWI561535B (en) * 2011-10-06 2016-12-11 Bvw Holding Ag Copolymers of hydrophobic and hydrophilic segments that reduce protein adsorption
RU2640911C2 (en) 2012-06-15 2018-01-12 Мерц Фарма Гмбх Унд Ко. Кгаа Method for obtaining of composition based on hyaluronic acid
CN102784414B (en) * 2012-08-02 2014-07-23 东华大学 Preparation method of injectable double-cross-linked hydrogel for tissue engineering
WO2014055895A1 (en) * 2012-10-05 2014-04-10 Allergan, Inc. Injectable device and method for sculpting, augmenting or correcting facial features such as the chin
CA2897353C (en) * 2013-01-17 2019-12-03 Jeffrey HAGEL Increasing muscular volume in a human using hyaluronic acid
US20140275340A1 (en) * 2013-03-15 2014-09-18 Lake Region Manufacturing, Inc. d/b/a Lake Region Medical Modified hyaluronate hydrophilic compositions, coatings and methods
US20140315828A1 (en) 2013-04-22 2014-10-23 Allergan, Inc. Cross-linked silk-hyaluronic acid compositions
EP3000836B1 (en) * 2013-05-22 2018-12-26 National Institute of Advanced Industrial Science and Technology Photodegradable crosslinking agent
EP3013865B1 (en) * 2013-06-28 2019-10-23 Galderma S.A. Method for manufacturing a shaped cross-linked hyaluronic acid product
CN103920182B (en) * 2014-04-16 2015-10-21 华熙福瑞达生物医药有限公司 A kind of biological absorbable haemostatic membrane
CN103923229B (en) * 2014-04-30 2016-02-03 苏州金诺生物技术有限公司 A kind of cross-linking hyaluronic acid sodium and preparation method thereof
WO2016128783A1 (en) 2015-02-09 2016-08-18 Allergan Industrie Sas Compositions and methods for improving skin appearance
WO2017001057A1 (en) 2015-06-30 2017-01-05 Merz Pharma Gmbh & Co. Kgaa Method of preparing a composition based on hyaluronic acid
KR20170090965A (en) * 2016-01-29 2017-08-08 한미약품 주식회사 Combination of crosslinked hyaluronic acids and a process for preparation thereof
CA3033536A1 (en) 2016-08-24 2018-03-01 Allergan, Inc. Co-crosslinked hyaluronic acid-silk fibroin hydrogels for improving tissue graft viability and for soft tissue augmentation
CN106589424B (en) * 2016-12-12 2020-06-02 华熙生物科技股份有限公司 Cross-linked hyaluronic acid gel for injection and preparation method thereof
CN110891611B (en) 2017-03-22 2024-03-29 阿森迪斯制药公司 Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
US20230190997A1 (en) 2017-06-26 2023-06-22 Evolved By Nature, Inc. Silk-hyaluronic acid based tissue filers and methods of using the same
CN109096483B (en) * 2017-06-28 2020-09-04 北京键凯科技股份有限公司 Branched polyglyol epoxy derivative cross-linked sodium hyaluronate gel and preparation and application thereof
JP2021522938A (en) 2018-05-09 2021-09-02 ザ ジョンズ ホプキンス ユニバーシティ Nanofiber-hydrogel complex for cell and tissue delivery
CA3099733A1 (en) 2018-05-09 2019-11-14 The Johns Hopkins University Nanofiber-hydrogel composites for enhanced soft tissue replacement and regeneration
CN113677320A (en) * 2018-12-19 2021-11-19 自然进化公司 Silk-hyaluronic acid tissue filler and methods of making and using the same
JP2022529953A (en) * 2019-04-19 2022-06-27 ジョインセラピュイティクス エッセ．エッレ．エッレ． Cross-linked polymer of functionalized hyaluronic acid and its use in the treatment of inflammatory conditions
KR102176486B1 (en) * 2019-06-14 2020-11-10 동국대학교 산학협력단 Method for Preparing an Ophathalmic Drug Carrier Based on Hyaluronic Acid
US11795320B2 (en) * 2019-09-20 2023-10-24 Bausch + Lomb Ireland Limited Grafted polymer and use thereof
CN112480483B (en) * 2020-11-27 2022-02-01 华熙生物科技股份有限公司 Preparation method of ectoin-hyaluronic acid composite gel and obtained product
AU2023206591A1 (en) 2022-01-11 2024-08-22 WiQo S.P.A. New hyaluronic acid derivatives as innovative fillers
EP4442733B1 (en) * 2022-01-14 2025-09-10 Jenkem Technology Co., Ltd. (Tianjin) Hyaluronic acid derivative or salt thereof, and preparation method therefor and application thereof
WO2025051155A1 (en) * 2023-09-05 2025-03-13 重庆金赛星医疗科技有限公司 Peg derivative cross-linked hyaluronic acid polymer, preparation method therefor and use thereof
CN117618672B (en) * 2023-12-06 2025-07-11 辽宁德玛生物科技有限公司 Preparation method of agarose gel for injection

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020091251A1 (en) * 1999-02-03 2002-07-11 Vitrolife Uk Limited Process for the production of multiple cross-linked hyaluronic acid derivatives
US20040127698A1 (en) * 2002-12-31 2004-07-01 Industrial Technology Research Institute Method for producing double-crosslinked hyaluronate material
US6852255B2 (en) * 2001-05-02 2005-02-08 Industrial Technology Research Institute Method for producing water-insoluble polysaccharides
US20090117070A1 (en) * 2004-06-23 2009-05-07 Angiotech Pharmaceuticals (Us), Inc. Methods and Crosslinked Polymer Compositions for Cartilage Repair

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2128827A (en) * 1938-03-09 1938-08-30 Frank B Killian Method and apparatus for manufacturing thin rubber articles
JPS4838158B1 (en) * 1970-10-05 1973-11-15
CA949965A (en) 1971-12-03 1974-06-25 Robert H. Marchessault Method of preparing cross-linked starch and starch derivatives
JPS6050128A (en) * 1983-08-25 1985-03-19 Daihachi Kagaku Kogyosho:Kk Extracting method of iron (iii) from aqueous solution and reverse extracting method of iron (iii) from extracting solvent
SE442820B (en) 1984-06-08 1986-02-03 Pharmacia Ab GEL OF THE CROSS-BOND HYALURONIC ACID FOR USE AS A GLASS BODY SUBSTITUTE
SE456346B (en) 1984-07-23 1988-09-26 Pharmacia Ab GEL TO PREVENT ADHESION BETWEEN BODY TISSUE AND SET FOR ITS PREPARATION
US4582865A (en) 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4605691A (en) 1984-12-06 1986-08-12 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4636524A (en) * 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
SE8501022L (en) * 1985-03-01 1986-09-02 Pharmacia Ab FORMAT CREATES AND PROCEDURES FOR ITS PREPARATION
US4713448A (en) 1985-03-12 1987-12-15 Biomatrix, Inc. Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues
FR2608456B1 (en) 1986-12-18 1993-06-18 Mero Rousselot Satia MICROCAPSULES BASED ON GELATIN AND POLYSACCHARIDES AND PROCESS FOR OBTAINING THEM
US5385938B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
FR2623167B2 (en) * 1987-08-14 1992-08-07 Genus Int IMPROVEMENT IN ARTICLES WITH ELASTIC ARTICULATIONS RIGIDIFYING ON THEIR TENSIONING
US5643464A (en) * 1988-11-21 1997-07-01 Collagen Corporation Process for preparing a sterile, dry crosslinking agent
US5475052A (en) * 1988-11-21 1995-12-12 Collagen Corporation Collagen-synthetic polymer matrices prepared using a multiple step reaction
SE462587B (en) * 1988-11-30 1990-07-23 Wiklund Henry & Co DEVICE FOR MARKING THE WORK PAPER WITH WRITTEN OR OTHER SIGNS
JPH02215707A (en) * 1989-02-15 1990-08-28 Chisso Corp Skin cosmetic
EP0398484B1 (en) * 1989-05-19 1995-05-31 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Alpha-glycosyl-L-ascorbic acid, and its preparation and uses
US5356883A (en) * 1989-08-01 1994-10-18 Research Foundation Of State University Of N.Y. Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use
EP0416250A3 (en) 1989-08-01 1991-08-28 The Research Foundation Of State University Of New York N-acylurea and o-acylisourea derivatives of hyaluronic acid
CA2023922A1 (en) 1989-09-05 1991-03-06 James M. Curtis Method of manufacturing an implantable article provided with a micropillared surface
JP2832848B2 (en) 1989-10-21 1998-12-09 株式会社林原生物化学研究所 Crystal 2-O-α-D-glucopyranosyl-L-ascorbic acid, its production method and use
US5246698A (en) * 1990-07-09 1993-09-21 Biomatrix, Inc. Biocompatible viscoelastic gel slurries, their preparation and use
US5143724A (en) * 1990-07-09 1992-09-01 Biomatrix, Inc. Biocompatible viscoelastic gel slurries, their preparation and use
JP3115625B2 (en) * 1991-03-30 2000-12-11 帝國製薬株式会社 Topical patch containing lidocaine
US5314874A (en) * 1991-04-19 1994-05-24 Koken Co., Ltd. Intracorporeally injectable composition for implanting highly concentrated cross-linked atelocollagen
BR9406190A (en) 1993-01-20 1996-01-09 Squibb & Sons Inc Alginate Fabric Alginate Fiber Process for preparing alginate fibers and dressing
DE784487T1 (en) * 1993-03-19 1999-11-04 Q-Med Ab, Uppsala A PREPARATION AND TISSUE PROPAGATION METHOD
US5531716A (en) * 1993-09-29 1996-07-02 Hercules Incorporated Medical devices subject to triggered disintegration
US5616568A (en) * 1993-11-30 1997-04-01 The Research Foundation Of State University Of New York Functionalized derivatives of hyaluronic acid
AU706434B2 (en) * 1994-10-18 1999-06-17 Ethicon Inc. Injectable liquid copolymers for soft tissue repair and augmentation
FR2733427B1 (en) 1995-04-25 2001-05-25 W K Et Associes INJECTABLE BIPHASIC COMPOSITIONS CONTAINING HYALURONIC ACID, ESPECIALLY USEFUL IN REPAIRING AND AESTHETIC SURGERIES
US6214331B1 (en) * 1995-06-06 2001-04-10 C. R. Bard, Inc. Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained
US5571503A (en) 1995-08-01 1996-11-05 Mausner; Jack Anti-pollution cosmetic composition
US6063405A (en) * 1995-09-29 2000-05-16 L.A.M. Pharmaceuticals, Llc Sustained release delivery system
IT1277707B1 (en) * 1995-12-22 1997-11-11 Chemedica Sa OPHTHALMIC FORMULATION BASED ON SODIUM HYALURONATE FOR USE IN OCULAR SURGERY
US5980948A (en) 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
US6066325A (en) * 1996-08-27 2000-05-23 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
IT1287967B1 (en) * 1996-10-17 1998-09-10 Fidia Spa In Amministrazione S PHARMACEUTICAL PREPARATIONS FOR LOCAL ANESTHETIC USE
FR2759577B1 (en) * 1997-02-17 1999-08-06 Corneal Ind DEEP SCLERECTOMY IMPLANT
FR2759576B1 (en) * 1997-02-17 1999-08-06 Corneal Ind PRE-DESCEMETIC SCLERO-KERATECTOMY IMPLANT
US5935164A (en) * 1997-02-25 1999-08-10 Pmt Corporaton Laminated prosthesis and method of manufacture
FR2764514B1 (en) * 1997-06-13 1999-09-03 Biopharmex Holding Sa IMPLANT INJECTED IN SUBCUTANEOUS OR INTRADERMAL WITH CONTROLLED BIORESORBABILITY FOR REPAIR OR PLASTIC SURGERY AND AESTHETIC DERMATOLOGY
US7192984B2 (en) * 1997-06-17 2007-03-20 Fziomed, Inc. Compositions of polyacids and polyethers and methods for their use as dermal fillers
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
FR2780730B1 (en) * 1998-07-01 2000-10-13 Corneal Ind INJECTABLE BIPHASIC COMPOSITIONS, ESPECIALLY USEFUL IN RESTORATIVE AND AESTHETIC SURGERIES
DK172900B1 (en) * 1998-12-18 1999-09-27 Per Julius Nielsen Preparation and kit for use in intraocular surgery
GB9902652D0 (en) * 1999-02-05 1999-03-31 Fermentech Med Ltd Process
US6767928B1 (en) * 1999-03-19 2004-07-27 The Regents Of The University Of Michigan Mineralization and biological modification of biomaterial surfaces
US6372494B1 (en) * 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
US6521223B1 (en) * 2000-02-14 2003-02-18 Genzyme Corporation Single phase gels for the prevention of adhesions
KR20010096388A (en) * 2000-04-19 2001-11-07 진세훈 Human glans enhancing materials and glans enhancing method
FR2811996B1 (en) * 2000-07-19 2003-08-08 Corneal Ind CROSS-LINKING OF POLYSACCHARIDE (S), PREPARATION OF HYDROGEL (S); POLYSACCHARIDE (S) AND HYDROGEL (S) OBTAINED, THEIR USES
US6773723B1 (en) * 2000-08-30 2004-08-10 Depuy Acromed, Inc. Collagen/polysaccharide bilayer matrix
US6620196B1 (en) * 2000-08-30 2003-09-16 Sdgi Holdings, Inc. Intervertebral disc nucleus implants and methods
US6924273B2 (en) * 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
JP2004510730A (en) * 2000-10-06 2004-04-08 ヤゴテック　アーゲー Parenterally administrable controlled release microparticle preparation
AU2001298061A1 (en) 2000-12-13 2003-07-09 Purdue Research Foundation Microencapsulation of drugs by solvent exchange
US6979440B2 (en) 2001-01-29 2005-12-27 Salvona, Llc Compositions and method for targeted controlled delivery of active ingredients and sensory markers onto hair, skin, and fabric
US7119062B1 (en) 2001-02-23 2006-10-10 Neucoll, Inc. Methods and compositions for improved articular surgery using collagen
CA2452412C (en) * 2001-06-29 2011-05-24 Medgraft Microtech, Inc. Biodegradable injectable implants and related methods of manufacture and use
US6749841B2 (en) * 2001-07-26 2004-06-15 Revlon Consumer Products Corporation Stabilized aqueous acidic antiperspirant compositions and related methods
JP4230135B2 (en) 2001-08-21 2009-02-25 独立行政法人科学技術振興機構 Method for producing glycosaminoglycan-collagen complex cross-linked by multifunctional cross-linking agent
US6780366B2 (en) * 2002-08-15 2004-08-24 Mentor Corporation Drip retainer
KR100507545B1 (en) * 2002-09-03 2005-08-09 주식회사 엘지생명과학 Hyaluronic acid derivatives and processes for preparing them
US20040127932A1 (en) 2002-09-12 2004-07-01 Shah Tilak M. Dip-molded polymeric medical devices with reverse thickness gradient, and method of making same
DE10246340A1 (en) * 2002-10-04 2004-04-29 Wohlrab, David, Dr. Combination preparation of hyaluronic acid and at least one local anesthetic and its use
US20040101959A1 (en) * 2002-11-21 2004-05-27 Olga Marko Treatment of tissue with undifferentiated mesenchymal cells
US20040199241A1 (en) 2002-12-30 2004-10-07 Angiotech International Ag Silk stent grafts
FR2861734B1 (en) * 2003-04-10 2006-04-14 Corneal Ind CROSSLINKING OF LOW AND HIGH MOLECULAR MASS POLYSACCHARIDES; PREPARATION OF INJECTABLE SINGLE PHASE HYDROGELS; POLYSACCHARIDES AND HYDROGELS OBTAINED
AU2003901834A0 (en) * 2003-04-17 2003-05-01 Clearcoll Pty Ltd Cross-linked polysaccharide compositions
JP2004323453A (en) 2003-04-25 2004-11-18 Chisso Corp Degradable gel and method for producing the same
JP4208843B2 (en) 2003-05-13 2009-01-14 三益半導体工業株式会社 Wafer isolation method, wafer isolation apparatus, and wafer isolation transfer machine
CN1829743B (en) 2003-07-30 2010-06-30 安特易斯有限公司 Biomedical composite matrices
EP1681306B1 (en) * 2003-10-29 2013-02-20 Teijin Limited Hyaluronic acid compound, hydrogel thereof and material for treating joint
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
AU2004293075A1 (en) * 2003-11-20 2005-06-09 Angiotech International Ag Soft tissue implants and anti-scarring agents
US8124120B2 (en) * 2003-12-22 2012-02-28 Anika Therapeutics, Inc. Crosslinked hyaluronic acid compositions for tissue augmentation
CA2550718C (en) * 2003-12-30 2013-11-05 Genzyme Corporation Cohesive gels from cross-linked hyaluronan and/or hylan, their preparation and use
DE102004002001A1 (en) * 2004-01-14 2005-08-11 Reinmüller, Johannes, Dr.med. Agent for the treatment of inflammatory diseases
JP2007519756A (en) * 2004-01-30 2007-07-19 アンジオテック インターナショナル アーゲー Compositions and methods for treating contracture
US20050226936A1 (en) 2004-04-08 2005-10-13 Q-Med Ab Method of soft tissue augmentation
US8288362B2 (en) * 2004-05-07 2012-10-16 S.K. Pharmaceuticals, Inc. Stabilized glycosaminoglycan preparations and related methods
ES2609105T3 (en) 2004-05-20 2017-04-18 Mentor Worldwide Llc Covalent linking method of hyaluronic acid and chitosan
CN101027065A (en) 2004-06-15 2007-08-29 陈献 Phospholipid compositions and methods for their preparation and use
AU2005272578A1 (en) * 2004-08-13 2006-02-23 Angiotech International Ag Compositions and methods using hyaluronic acid and hyluronidase inhibitors
US7414021B2 (en) 2004-10-01 2008-08-19 Vincent Carmine Giampapa Method and composition for restoration of age related tissue loss in the face or selected areas of the body
KR100762928B1 (en) * 2004-10-29 2007-10-04 재단법인서울대학교산학협력재단 Non-woven form of bone tissue-induced regeneration shielding membrane made of silk fibroin nanofibers and method for manufacturing same
FR2878444B1 (en) * 2004-11-30 2008-04-25 Corneal Ind Soc Par Actions Si VISCOELASTIC SOLUTIONS COMPRISING SODIUM HYALURONATE AND HYDROXYPROPYLMETHYLCELLULOSE, PREPARATION AND USES
EP1893174A2 (en) 2005-05-10 2008-03-05 Cytophil, Inc. Injectable hydrogels and methods of making and using same
EP1726299A3 (en) 2005-05-27 2007-04-18 StratoSphere Pharma AB Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
EP1932530A4 (en) * 2005-08-11 2009-04-29 Hayashibara Biochem Lab AGENT ENHANCING COLLAGEN PRODUCTION AND USE THEREOF
JP4982718B2 (en) 2005-08-31 2012-07-25 株式会社林原 Composition for oral intake for beautiful skin
EP3015101B1 (en) * 2005-10-03 2019-08-21 PINSKY, Mark A. Non-phospholipid liposomes comprising hyaluronic acid
US20070203095A1 (en) * 2005-12-14 2007-08-30 Anika Therapeutics, Inc. Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
FR2894827B1 (en) * 2005-12-21 2010-10-29 Galderma Res & Dev PHARMACEUTICAL OR COSMETIC PREPARATIONS FOR TOPICAL AND / OR PARENTERAL APPLICATION, PROCESSES FOR THEIR PREPARATION, AND USES THEREOF
US20070184087A1 (en) * 2006-02-06 2007-08-09 Bioform Medical, Inc. Polysaccharide compositions for use in tissue augmentation
US20070212385A1 (en) * 2006-03-13 2007-09-13 David Nathaniel E Fluidic Tissue Augmentation Compositions and Methods
WO2007109069A2 (en) * 2006-03-15 2007-09-27 Surmodics, Inc. Hydrophobic derivatives of natural biodegradable polysaccharides and uses thereof
US20070298005A1 (en) 2006-06-22 2007-12-27 Marie-Josee Thibault Injectable composition for treatment of skin defects or deformations
WO2008034176A1 (en) * 2006-09-19 2008-03-27 Ultraceuticals R & D Pty Ltd Cross-linked polysaccharide gels
FR2908415B1 (en) 2006-11-10 2009-01-23 Abr Dev Sarl RETICULATED HYALURONIC ACID AND PROCESS FOR PREPARING THE SAME
KR100759091B1 (en) 2006-12-13 2007-09-17 조강선 Skin filler composition
WO2008098007A1 (en) * 2007-02-05 2008-08-14 Freedom-2, Inc. Tissue fillers and methods of using the same
US7776840B2 (en) * 2007-02-21 2010-08-17 Cutanea Life Sciences, Inc. Methods of use of biomaterial and injectable implant containing biomaterial
US7939578B2 (en) * 2007-02-23 2011-05-10 3M Innovative Properties Company Polymeric fibers and methods of making
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
AU2008256819A1 (en) * 2007-05-23 2008-12-04 Allergan, Inc. Cross-linked collagen and uses thereof
WO2008147817A2 (en) * 2007-05-23 2008-12-04 Allergan, Inc. Coated hyaluronic acid particles
EP2182971B1 (en) * 2007-07-27 2013-12-18 Humacyte, Inc. Compositions comprising human collagen and human elastin and uses thereof
US8318695B2 (en) * 2007-07-30 2012-11-27 Allergan, Inc. Tunably crosslinked polysaccharide compositions
FR2920000B1 (en) 2007-08-13 2010-01-29 Oreal COSMETIC OR PHARMACEUTICAL COMPOSITION CONTAINING HYALURONIC ACID, AND COSMETIC PROCESS FOR DECREASING SIGNS OF AGING
US8697044B2 (en) * 2007-10-09 2014-04-15 Allergan, Inc. Crossed-linked hyaluronic acid and collagen and uses thereof
US7910134B2 (en) * 2007-10-29 2011-03-22 Ayman Boutros Alloplastic injectable dermal filler and methods of use thereof
US20090143348A1 (en) * 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
US8394784B2 (en) * 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
US8394782B2 (en) * 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
FR2924615B1 (en) 2007-12-07 2010-01-22 Vivacy Lab HYDROGEL COHESIVE BIODEGRADABLE.
US9161970B2 (en) * 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
CA2706553A1 (en) * 2007-12-26 2009-07-09 Mark A. Pinsky Collagen formulations for improved skin care
US20090291986A1 (en) 2008-05-22 2009-11-26 Apostolos Pappas Composition and method of treating facial skin defect
US20090297632A1 (en) 2008-06-02 2009-12-03 Waugh Jacob M Device, Methods and Compositions to Alter Light Interplay with Skin
US8450475B2 (en) * 2008-08-04 2013-05-28 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
US20100111919A1 (en) * 2008-10-31 2010-05-06 Tyco Healthcare Group Lp Delayed gelation compositions and methods of use
US20100136070A1 (en) * 2008-12-03 2010-06-03 Jakk Group, Inc. Methods, devices, and compositions for dermal filling
ES2662064T3 (en) 2009-03-30 2018-04-05 Scivision Biotech Inc. Method for producing crosslinked hyaluronic acid

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020091251A1 (en) * 1999-02-03 2002-07-11 Vitrolife Uk Limited Process for the production of multiple cross-linked hyaluronic acid derivatives
US6852255B2 (en) * 2001-05-02 2005-02-08 Industrial Technology Research Institute Method for producing water-insoluble polysaccharides
US20040127698A1 (en) * 2002-12-31 2004-07-01 Industrial Technology Research Institute Method for producing double-crosslinked hyaluronate material
US20090117070A1 (en) * 2004-06-23 2009-05-07 Angiotech Pharmaceuticals (Us), Inc. Methods and Crosslinked Polymer Compositions for Cartilage Repair

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9265761B2 (en) 2007-11-16 2016-02-23 Allergan, Inc. Compositions and methods for treating purpura
US8853184B2 (en) 2007-11-30 2014-10-07 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US10328180B2 (en) 2008-08-04 2019-06-25 Allergan Industrie, S.A.S. Hyaluronic acid-based gels including lidocaine
US11020512B2 (en) 2008-08-04 2021-06-01 Allergan Industrie, Sas Hyaluronic acid-based gels including lidocaine
US10391202B2 (en) 2008-08-04 2019-08-27 Allergan Industrie Sas Hyaluronic acid-based gels including lidocaine
US11173232B2 (en) 2008-08-04 2021-11-16 Allergan Industrie, Sas Hyaluronic acid-based gels including lidocaine
US9089519B2 (en) 2008-08-04 2015-07-28 Allergan Industrie Sas Hyaluronic acid-based gels including lidocaine
US10485896B2 (en) 2008-08-04 2019-11-26 Allergan Industrie Sas Hyaluronic acid-based gels including lidocaine
US9238013B2 (en) 2008-08-04 2016-01-19 Allergan Industrie, Sas Hyaluronic acid-based gels including lidocaine
US9358322B2 (en) 2008-08-04 2016-06-07 Allergan Industrie Sas Hyaluronic acid-based gels including lidocaine
US11154484B2 (en) 2008-09-02 2021-10-26 Allergan Holdings France S.A.S. Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
US9228027B2 (en) 2008-09-02 2016-01-05 Allergan Holdings France S.A.S. Threads of Hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
US9333160B2 (en) 2010-01-13 2016-05-10 Allergan Industrie, Sas Heat stable hyaluronic acid compositions for dermatological use
US10220113B2 (en) 2010-01-13 2019-03-05 Allergan Industrie, Sas Heat stable hyaluronic acid compositions for dermatological use
US10806821B2 (en) 2010-01-13 2020-10-20 Allergan Industrie, Sas Heat stable hyaluronic acid compositions for dermatological use
US9855367B2 (en) 2010-01-13 2018-01-02 Allergan Industrie, Sas Heat stable hyaluronic acid compositions for dermatological use
US8921338B2 (en) 2010-03-12 2014-12-30 Allergan Industrie, Sas Fluid compositions for improving skin conditions
US10905797B2 (en) 2010-03-22 2021-02-02 Allergan, Inc. Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US11083684B2 (en) 2011-06-03 2021-08-10 Allergan Industrie, Sas Dermal filler compositions
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US9962464B2 (en) 2011-06-03 2018-05-08 Allergan, Inc. Dermal filler compositions including antioxidants
US9950092B2 (en) 2011-06-03 2018-04-24 Allergan, Inc. Dermal filler compositions for fine line treatment
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US11000626B2 (en) 2011-06-03 2021-05-11 Allergan Industrie, Sas Dermal filler compositions including antioxidants
US10624988B2 (en) 2011-06-03 2020-04-21 Allergan Industrie, Sas Dermal filler compositions including antioxidants
US10994049B2 (en) 2011-06-03 2021-05-04 Allergan Industrie, Sas Dermal filler compositions for fine line treatment
US9737633B2 (en) 2011-06-03 2017-08-22 Allergan, Inc. Dermal filler compositions including antioxidants
US11844878B2 (en) 2011-09-06 2023-12-19 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
US10434214B2 (en) 2011-09-06 2019-10-08 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US11833269B2 (en) 2011-09-06 2023-12-05 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US10722444B2 (en) 2014-09-30 2020-07-28 Allergan Industrie, Sas Stable hydrogel compositions including additives
US12324868B2 (en) 2015-02-13 2025-06-10 Allergan Industrie, Sas Implants for sculpting, augmenting or correcting facial features such as the chin
CN107936272A (en) * 2017-11-27 2018-04-20 华熙福瑞达生物医药有限公司 A kind of preparation method of 3D cross-linked-hyaluronic acid salt gels for radiotherapy protection and products thereof
CN107955194A (en) * 2017-11-29 2018-04-24 桂林华诺威生物科技有限公司 The preparation method of high quality cross-linking sodium hyaluronate gel
WO2019130358A1 (en) * 2017-12-29 2019-07-04 Matex Lab S.P.A. Method to prepare a filler with a hyaluronic acid base
US11491098B2 (en) 2017-12-29 2022-11-08 Matex Lab S.P.A. Method to prepare a filler with a hyaluronic acid base
US11530302B2 (en) 2017-12-29 2022-12-20 Matex Lab S.P.A. Method to prepare a filler with a hyaluronic acid base using specific crosslinking agents
KR102524417B1 (en) 2017-12-29 2023-04-24 마텍스 랩 에스.피.에이 Method for preparing a filler having a hyaluronic acid base using a specific crosslinking agent
CN111918639A (en) * 2017-12-29 2020-11-10 马特克斯拉比有限公司 Method for preparing filling having hyaluronic acid group using specific cross-linking agent
WO2019130357A1 (en) * 2017-12-29 2019-07-04 Matex Lab S.P.A. Method to prepare a filler with a hyaluronic acid base using specific crosslinking agents
KR20200128382A (en) * 2017-12-29 2020-11-12 마텍스 랩 에스.피.에이 Method for preparing a filler having a hyaluronic acid base by using a specific crosslinking agent
CN108774329A (en) * 2018-06-13 2018-11-09 浙江景嘉医疗科技有限公司 A kind of preparation method of medical cross-linking sodium hyaluronate gel

Also Published As

Publication number Publication date
EP2178923A1 (en) 2010-04-28
AU2008282541B2 (en) 2013-09-26
JP2010535277A (en) 2010-11-18
NZ583031A (en) 2012-05-25
US8318695B2 (en) 2012-11-27
JP5518709B2 (en) 2014-06-11
JP2014194018A (en) 2014-10-09
WO2009018076A1 (en) 2009-02-05
CN101790542A (en) 2010-07-28
MX2010001219A (en) 2010-03-01
CN101790542B (en) 2014-03-12
NZ599888A (en) 2013-08-30
AU2008282541A1 (en) 2009-02-05
CN102850468A (en) 2013-01-02
HK1142917A1 (en) 2010-12-17
BRPI0815045A2 (en) 2015-02-10
CA2695179A1 (en) 2009-02-05
KR20100046038A (en) 2010-05-04
US20090036403A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
US8318695B2 (en) Tunably crosslinked polysaccharide compositions
Li et al. Self-healing hyaluronic acid hydrogels based on dynamic Schiff base linkages as biomaterials
CN103974722B (en) Water insoluble gel composition and method for preparing same
EP1163274B1 (en) Process for cross-linking hyaluronic acid to polymers
CA2361981C (en) Process for the production of multiple cross-linked hyaluronic acid derivatives
Li et al. Enzymatically crosslinked and mechanically tunable silk fibroin/pullulan hydrogels for mesenchymal stem cells delivery
AU2014301493B2 (en) A process for preparing a cross-linked hyaluronic acid product
CA2572127C (en) Hydrogels of hyaluronic acid and alpha, beta-polyaspartylhydrazide and their biomedical and pharmaceutical uses
CN110078941A (en) A kind of modifted-nano-hydroxyapatite supermolecule composite hydrogel and preparation method
CN104231285A (en) Hyaluronic acid derivative gel and preparing method thereof
AU2013273820A1 (en) Tunably crosslinked hyaluronic acid compositions
HK1142917B (en) Tunably crosslinked hyaluronic acid compositions
CN119371682B (en) A cationic silk fibroin/sodium oxidized hyaluronic acid injectable hydrogel, its preparation method and application
CN119081158A (en) A method for preparing a bio-based wet adhesion hydrogel
CN119708507A (en) Novel cross-linking agent, hyaluronic acid soft tissue filler and preparation method
CN118056860A (en) Water gel composition, preparation method thereof and water gel material
CN116997371A (en) Implantable or injectable polymer-based products and methods of making same
Piluso Design of biopolymer-based networks with defined molecular architecture

Legal Events

Date Code Title Description
AS Assignment

Owner name: ALLERGAN, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:STROUMPOULIS, DIMITRIOS;TEZEL, AHMET;REEL/FRAME:034096/0455

Effective date: 20071206

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION